Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients (MAVIS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01546571
Recruitment Status : Terminated (Planned interim analysis showed a strong signal of efficacy in a pre-specified patient population. Fast track designation was granted and a new, redesigned pivotal trial will be conducted.)
First Posted : March 7, 2012
Last Update Posted : December 8, 2021
Information provided by (Responsible Party):
Polynoma LLC